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Summary: Whole-genome sequencing of ocular Chlamydia trachomatis from Amhara, Ethiopia found no 
evidence of macrolide-resistance, despite five years of trachoma control interventions, including mass 
distribution of azithromycin. Polymorphisms in ompA were associated with prevalence of ocular infection and 
trachomatous disease. 
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Abstract 
To eliminate trachoma as a public health problem, the WHO recommends the SAFE (Surgery, Antibiotics, 
Facial cleanliness, and Environmental improvement) strategy. As part of the SAFE strategy in the Amhara 
Region, Ethiopia, the Trachoma Control Program distributed over 124 million doses of antibiotic between 2007 
and 2015. Despite this, trachoma remained hyperendemic in many districts and a considerable level of 
Chlamydia trachomatis (Ct) infection was evident.  
We utilised residual material from Abbott m2000 Ct diagnostic tests to sequence 99 ocular Ct samples from 
Amhara and investigated the role of Ct genomic variation in continued transmission of Ct.  
Sequences were typical of ocular Ct, at the whole-genome level and in tissue tropism-associated genes. There 
was no evidence of macrolide-resistance in this population. Polymorphism around ompA gene was associated 
with village-level trachomatous inflammation-follicular prevalence. Greater ompA diversity at the district-level 
was associated with increased Ct infection prevalence.  
We found no evidence for Ct genomic variation contributing to continued transmission of Ct after treatment, 
adding to evidence that azithromycin does not drive acquisition of macrolide resistance in Ct. Increased Ct 
infection in areas with more ompA variants requires longitudinal investigation to understand what impact this 
may have on treatment success and host immunity.  
 
Keywords: trachoma, Chlamydia trachomatis, antimicrobial resistance, genomics, whole-genome sequencing, 
mass drug administration, azithromycin, neglected tropical disease 
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Background 
Trachoma is a blinding disease caused by Chlamydia trachomatis (Ct). To eliminate trachoma as a public health 
problem, the WHO recommends the SAFE (Surgery, Antibiotics, Facial cleanliness, and Environmental 
improvement) strategy [1]. This includes annual mass drug administration (MDA) of azithromycin to 
individuals aged 6 months and topical tetracycline eye ointment for pregnant women and children aged <6 
months. The number of recommended years of interventions is based on prevalence of trachoma in a district [2]. 
For districts considered hyperendemic for trachoma, defined as a trachomatous inflammation-follicular (TF) 
prevalence of ≥ 30% among children aged 1-9 years, 5-7 years of SAFE are recommended followed by further 
population-based surveys to determine the impact of the interventions.  
As part of the SAFE strategy in Amhara National Regional State, Ethiopia, the Trachoma Control Program 
distributed over 124 million doses of antibiotic from 2007-2015 [3]. Both administrative and self-reported 
coverage have demonstrated treatment coverage close to or above the WHO recommended threshold of 80% [3–
5]. The program also provided health education and assisted in the construction of latrines as part of the F and E 
components of SAFE [3]. Despite an average of 5 years of these interventions, trachoma remained 
hyperendemic in many districts, with considerable levels of Ct infection [6].  
Historically, Ct molecular epidemiology focused on ompA,[7] which encodes the major outer membrane protein. 
More recently multilocus sequence typing schemes have been used [8,9]. Since 2010, there has been a rapid 
expansion of Ct whole-genome sequencing (WGS), due to the ability to sequence directly from clinical samples 
[10,11]. Despite more than seven-hundred Ct genomes being sequenced [12–15], few studies have evaluated the 
role of genome-level variation in Ct transmission and outcomes of infection. Recent publications have begun to 
address these questions in Ct from trachoma-endemic settings [15,16]. WGS additionally allows monitoring of 
antimicrobial resistance in Ct [16–18], which is of critical importance as MDA with azithromycin is key for 
trachoma control, and is under consideration as an intervention for childhood mortality [19], neonatal sepsis 
[20], and malaria [21]. 
The Trachoma Control Program in Amhara has conducted multiple studies to better understand the 
epidemiology of trachoma in communities that have received approximately 5 years of annual MDA, yet still 
have significant levels of Ct infection and disease. This study sequenced 99 ocular Ct samples from Amhara to 
identify antimicrobial resistance alleles and investigate the role of genomic variation in the continued 
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transmission of Ct. We further explored the relationship between Ct genomic variation, ocular Ct infection 
prevalence, and trachomatous disease prevalence at the village and district-level. 
Methods 
Study design and population 
Between 2007 and 2010 the SAFE strategy was scaled to reach all Amharan districts with interventions 
administered for 5 years. Methodology for these district-level surveys has been published previously [3]. 
Briefly, a multi-stage cluster randomized methodology was used, whereby clusters (villages) were selected 
using a population proportional to estimated size method, and within a cluster, a segmentation approach was 
used to randomly select 30-40 households [3]. 
After enumerating all residents, consented residents were examined for trachoma. Every-other cluster was 
chosen for swab collection prior to surveying a district, and during the house-to-house survey, the first 25 
children aged 1-5 years with parental consent were swabbed for the presence of infection. If more than one child 
aged 1-5 years lived in a household, one child was randomly chosen by survey software.   
Sample collection and processing 
Gloved graders swabbed the upper tarsal conjunctiva three times with a polyester-tipped swab, rotating 120 
degrees along the swab's axis each time to collect a sufficient epithelial specimen [6]. Samples were transferred 
to the Amhara Public Health Institute (APHI) and stored at -20º C. Conjunctival swabs from each district were 
randomized and five samples were combined into each pool. Pools were processed with the RealTime PCR 
assay on the Abbott m2000 system at the APHI laboratory [6]. All individual samples from positive pools from 
North Gondar, South Gondar, East Gojam, and Waghemra were processed again to provide individual-level data 
[22]. Samples from these zones were prioritized owing to the persistent high trachoma prevalence. For positive 
individual samples, the PCR cycle threshold was converted to  Ct elementary body (EB) equivalent 
concentration based on a calibration curve of known EB concentrations on the RealTime Assay [22].  
Once Ct load was known for the positive individual samples, a total of 240 with the highest load were chosen 
for this project. Samples with sufficient Ct load, likely to obtain high quality full genome sequence data based 
on our previous studies, were re-extracted as described below [15,16,23]. 
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Ct detection and sequencing preparation 
DNA was extracted from 800 µl residual material per sample from Abbott m2000 diagnostic tests using 
QIAamp mini DNA kit. Samples were quantified using a genome target by qPCR [24]. Samples with ≥ 10 
genome copies per µl of DNA were considered for WGS. 
 
Sequencing, processing, and analysis of Ct 
Sequencing was performed as previously described [15] except we utilised the SureSelectXT Low Input kit. 
Processing and analysis of sequenced reads was performed as previously described [16]. Briefly, raw reads were 
trimmed and filtered using Trimmomatic. Filtered reads were aligned to a reference genome (A/Har13) with 
Bowtie2, variants were called with SAMtools/BCFtools. Multiple genome and plasmid alignments were 
generated using progressiveMauve, multiple gene alignments were generated using MUSCLE. Phylogenies 
were computed using RAxML, predicted regions of recombination were masked using Gubbins. Domain 
structure of tarP and truncation of trpA were characterised as previously described [15]. ABRicate and the 
ResFinder database were used to identify antimicrobial resistance genes in the reference-assembled genomes 
and de novo assembled reads. 
 
Genome-wide association analyses 
Genome-wide association analysis (GWAS) was performed to identify polymorphisms specific to this 
population of ocular Ct sequences through comparison of 99 Amharan Ct genomes to 213 previously sequenced 
samples from trachoma-endemic communities. Heterozygous calls and positions with greater than 25% missing 
data were removed. Polymorphisms were considered conserved in Amhara if the major allele frequency was > 
0.8 and rare in the representative ocular population if the same allele was at a frequency < 0.2. The final analysis 
included 116 single nucleotide polymorphisms (SNPs). A logistic regression was performed with each Amhara-
specific site as the independent variable and origin of the sequence as the dependent variable (reference level; 
representative and comparator level; Amharan). P-values were Bonferroni corrected. 
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GWAS was performed to identify Ct polymorphisms associated with village-level clinical data. Heterozygous 
base calls were and positions with a minor allele frequency of less than 25% or greater than 25% missing data 
were removed. The final analysis included 681 SNPs. A linear regression was performed with each SNP as the 
independent variable and village-level Ct infection, TF, or TI prevalence as the dependent variable.  District was 
included as a random-effect and with adjustment for age and gender. P-values were Bonferroni corrected. 
Additionally, a sliding-window approach was used to identify polymorphic regions of the genome. Windows of 
10 kilobases were evaluated, with a step size of 1 kilobase. The final analysis included 907 polymorphic 
regions. A linear regression was performed with each polymorphic region collapsed into a pseudo-haplotype per 
sequence as the independent variable, including district as a random-effect and adjusted for age and gender. This 
model was compared to a model including only the covariates and random-effects by F-test. P-values were 
Bonferroni corrected. 
 
Inference of ompA sequences 
Complete sequences of ompA were obtained from whole-genome sequence data using the reference-based 
assembly method described above with one change. Each sample was assembled against four reference 
sequences (A/Har-13, B/Jali-20, C/TW-3, and D/UW-3) and the assembly with the highest coverage was used 
for downstream analyses. Serovar of ompA was assigned using maximum blastn homology against all published 
Ct sequences. Genotypes of ompA were manually determined using SeaView. Diversity of ompA genotypes was 
calculated as Simpson’s D using vegan in R. 
Results 
Ocular swabs previously confirmed as positive for Ct DNA were selected for this study (n = 240), samples with 
sufficiently high concentration of Ct DNA after re-extraction were considered for WGS (n = 135). Of these, 99 
were randomly selected for sequencing to match the complete dataset on age, gender, and zone of collection. 
The sequenced and complete samples were comparable (Table 1), except as expected a higher median load of 
infection in sequenced samples. 
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The Amharan Ct genomes formed two subclades within the T2 ocular clade (Figure 1). The two subclades were 
predominantly separated by ompA genotype, with 52 serovar A (SvA) and 47 serovar B (SvB) genomes. 
Focusing on genomes from ocular infections (SI Figure 2), the SvA Amharan genomes branch together 
independent from any previously sequenced Ct. The SvB Amharan genomes were split across two branches. 
One branch was most closely related to A/Har-13, isolated from Saudi Arabia. The second, smaller branch was 
most closely related to Ba/Apache-2 from the USA as well as recently sequenced ocular Ct from Solomon 
Islands.  
 
Several Ct genes and genomic regions are hypothesised to be indicative of tissue tropism, with polymorphisms 
distinct to ocular, urogenital and LGV sequences. All Amharan Ct genomes had tarP domain structure typical of 
ocular sequences [25]. Similarly, all Amharan genomes had inactivating mutations in trpA, leading to a non-
functional tryptophan synthase [26]. Polymorphic membrane proteins clustered phylogenetically with ocular 
isolates (SI Figure 2) [27]. There was minimal polymorphism in the Ct plasmid within the Amharan genomes 
and they were closely related to previously sequenced ocular isolates (SI Figure 3). There was no evidence for 
the presence of macrolide-resistance alleles in the assembled genomes or de novo assembled reads. 
 
Amharan Ct genomes were compared to 213 previously sequenced samples from trachoma-endemic 
communities to identify genomic markers specific to Amhara.[12–16,23] Of 36,805 polymorphic sites (Figure 
2a), 116 were conserved in Amhara (frequency ≥ 0.8) and rare in the representative ocular population 
(frequency ≤ 0.2). These were dispersed throughout the genome (Figure 2b). Fourteen genes harboured two such 
sites and five genes contained three sites, all of which have previously been identified as polymorphic in distinct 
populations of Ct (Figure 2c). 
 
A GWAS was performed to identify polymorphism within the Amharan Ct genomes related to village-level 
prevalence of Ct infection. The analysis included 681 single nucleotide polymorphisms (SNPs) in 99 genomes. 
No SNPs were associated with village-level prevalence of infection (SI Figure 4). A secondary sliding-window 
approach was utilised to identify polymorphic regions of the genome associated with infection prevalence. The 
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analysis included 907 polymorphic regions in 99 genomes. No polymorphic regions were associated with 
village-level prevalence of infection (SI Figure 4).  
 
No SNPs were associated with village-level prevalence of TF (Figure 3a). However, eight polymorphic regions 
from positions 774,000-791,000 were associated with TF prevalence (Figure 3b). SNPs in these regions were 
focused in CTA0743/pbpB (harbouring 29 SNPs), CTA0747/sufD (10 SNPs) and CTA0742/ompA (7 SNPs). All 
SNPs in sufD were synonymous, while 8/29 and 3/7 SNPs in pbpB and ompA were non-synonymous. 
 
No SNPs or polymorphic regions were associated with village-level prevalence of TI (SI Figure 5). 
 
As ompA variation was important in Ct phylogeny and heterogeneity in TF profiles, we further investigated the 
geographical distribution of ompA serovars and their relationship to levels of Ct infection and TF. SvA and SvB 
of ompA were distributed across all zones (Figure 4). Village-level Ct infection, TF and TI prevalence were not 
associated with ompA serovar (p = 0·860, 0·382 and 0·177 respectively). We identified nine ompA types in this 
population (Table 2). Six were SvA, defined by nine non-synonymous polymorphisms. Three were SvB, defined 
by two non-synonymous polymorphisms. Four of nine types were present in all zones (A1, A3, A5 and B3), 
four were exclusive to East Gojam (A2, A4, A6 and B1) and one was found in East Gojam and North Gondar 
(B2) (SI Figure 6). Types A1 (n = 5) and B1 (n = 6) had a nucleotide predicted amino acid change in the 
surface-exposed, variable domain 1 (VD1),  A2 (n = 2) in VD2 and A4 (n = 1) in VD4.  
 
Most villages (55/61) had only one ompA type in this study, therefore we evaluated ompA diversity at the 
district-level, using Simpson’s D and adjusting for number of genomes sampled per district. We used published 
Ct infection, TF and TI prevalence estimates [6,28] (Table 3). Ct infection and TI prevalence were significantly 
higher with increasing ompA diversity, a similar trend was found for TF prevalence. In a multivariate model, 
only Ct infection prevalence was associated with increasing ompA diversity. 
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Discussion 
This study sequenced Ct from ocular samples collected from districts in Amhara, Ethiopia which had received 
approximately 5 years of the SAFE strategy, as part of trachoma control efforts. We found sequences were 
typical of ocular Ct, at both the whole-genome level and in tropism-associated genes, yet phylogenetically 
distinct from most previously sequenced Ct genomes. There was no evidence of macrolide-resistance alleles in 
this ocular Ct population. Greater ompA diversity at the district-level was associated with increased Ct infection 
prevalence.  A continued commitment to the implementation of the SAFE strategy with consideration of 
enhanced MDA accompanied by further longitudinal investigation is warranted in Amhara.  
 
Almost 900 million doses of azithromycin have been distributed by trachoma control programmes since 1999 
and in Amhara 15 million doses are administered annually [3]. Mass distribution of azithromycin is likely to 
become more common as evidence grows of off-target effects such as reducing infectious diseases [21,29], 
diarrheal diseases [30] and childhood mortality [20,31,32]. There is concern about the impact of these 
programmes on development of antimicrobial resistance in [18,33]. This is particularly true where community-
wide treatment with azithromycin has been unable to eliminate trachoma as a public health problem within 
expected timelines [30,34]. It has been shown that treating communities with azithromycin can increase 
nasopharyngeal carriage of macrolide-resistant Staphylococcus [35] and Streptococcus [36] and alters the faecal 
microbiome [37,38], with reports of increased macrolide-resistant Escherichia coli [39]. This study, in 
agreement with previous work [16–18] found no evidence of macrolide-resistance in this Ct population. While 
encouraging, it does not rule out macrolide-resistance as a potential problem in these communities. Carriage of 
macrolide-resistant pathogens in the gut and nasopharynx may be impacted by antibiotic treatment. 
Additionally, presence of additional species of Chlamydia [40,41] and non-chlamydial bacteria [42–45] in the 
ocular niche have been associated with trachoma, therefore resistance in other bacteria may be important. 
 
No Ct genomes in this study had acquired azithromycin resistance alleles, however, there may be other genomic 
factors which support Ct transmission after treatment.  To explore this, we compared Amharan Ct genomes with 
previously sequenced Ct to find polymorphism specific to this population that could explain continued 
transmission. The few SNPs identified as specific to Amhara were dispersed across the genome in known 
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polymorphic genes, rather than being overrepresented in genes related to Ct survival. The typical nature of this 
Ct population was supported by phylogenetic clustering with other ocular Ct sequences, presence of a non-
functional tryptophan synthase operon and tropism-associated polymorphism in tarP and the polymorphic 
membrane proteins. Similarly to recent studies from distinct trachoma-endemic communities [12–16,23], the Ct 
sequences in this population formed two closely related subclades within the ocular clade, primarily separated 
by ompA serovar. Evidence of phylogenetic clustering by country of collection and the similarity to Ct 
sequences collected over 50 years prior to this study suggests diversification in ocular Ct is slow and geography-
related, rather than driven by treatment-derived selection pressure. A surprising finding in this study was that a 
subgroup of SvB Ct from Amhara were most closely related to a historical genome from USA (Ba/Apache-2) 
and recently collected genomes from Solomon Islands [23]. It is possible the origin of these genomes is unique 
within this population; however, it is more likely that this is further evidence of the slow diversification of Ct. In 
support of this, ompA SvB sequences were significantly less diverse than SvA in this study. Furthermore, all 
major branches of ocular Ct phylogeny studied here included samples collected decades apart from 
geographically disparate sites.  
 
We identified several polymorphic regions associated with village-level TF prevalence. The polymorphisms 
were mostly frequently found in ompA, pbpB and sufD, all of which are known to be polymorphic. OmpA 
encodes the major outer membrane protein which is the primary target of host immune responses and is believed 
to function as an adhesin and/or porin [46]. The functions of pbpB and sufD in Ct are unknown, bacterial 
homologues of these genes function in peptidoglycan synthesis and response to oxidative stress respectively. It 
is plausible that genes hypothesised to be involved in immune evasion and response to stress could impact Ct 
survival and response to treatment.  
 
We found approximately equal representation of SvA and SvB in this study. Both serovars were present in all 
districts and were not associated with village-level Ct infection, TF, or TI prevalence. However, Ct infection 
prevalence was increased in districts with greater ompA diversity. Our data agrees with a  Nepalese study that 
found increased ompA diversity in villages to be associated with higher trachoma prevalence [47]. In contrast, a 
more recent study from Ethiopia found no association between ompA diversity and Ct infection levels [48]. It is 
known immunity to Ct is serovar-specific [49,50], therefore it is plausible that in villages with multiple serovar 
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in circulation, individuals are more likely to be exposed to a serovar they do not have protective immunity 
against. Presence of one or more ompA variants should not impact treatment success, however, it is possible that 
higher levels of Ct infection pre-treatment, driven by presence of multiple serovars, could increase the 
likelihood of low-level transmission persisting after treatment. 
 
A potential limitation of this study was bias towards samples with higher Ct load. It is possible that relationships 
between ompA variation and Ct infection prevalence might have been different if lower load infections were 
included, particularly at the village-level, as the majority (34/61) were represented by one sequence. We have 
also not sequenced material from Abbott m2000 specimens previously, it is possible that long-term storage in 
this format and multiple freeze-thaw cycles may have impacted DNA quality or quality. However, obtaining 
high quality genomes from all sequenced samples, with as low as 500 Ct genomes input, suggests quality was 
not an issue. Additionally, our sample size was restricted by both Ct load and the cost of sequencing. This is the 
largest collection of ocular Ct genomes from a single geographical population, but it is still possible that we may 
have missed some smaller effects in the genome-wide analyses due to limited statistical power. Lastly, while 
study villages were randomly selected using standard programmatic methods and subsampling was matched for 
zone of collection, the conclusions of this study may have been different if we had been able to sequence a 
larger and more geographically diverse population of Ct. 
 
Despite approximately five years of azithromycin MDA, we found no evidence for Ct genomic variation 
contributing to continued transmission of Ct, adding to evidence that azithromycin MDA does not drive 
acquisition of macrolide-resistance alleles in Ct. This study demonstrates feasibility of WGS of low-load, 
residual material and highlights the added value of collecting ocular swabs as part of trachoma surveys. 
Collection and long-term storage of these samples has helped alleviate concerns of azithromycin resistance in 
Amharan Ct, while offering important insights into the relationship between ompA variation and Ct infection 
levels. Future longitudinal investigation will be needed to understand what impact ompA diversity may have on 
treatment success in Amhara and other trachoma-endemic regions. 
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Figure legends 
Figure 1. 
Maximum likelihood reconstruction of whole genome phylogeny of ocular Chlamydia trachomatis (Ct) 
sequences from Amhara, Ethiopia. Whole genome phylogeny of 99 Ct sequences from Amhara and 183 Ct 
clinical and reference strains. Amharan Ct sequences were mapped to Ct A/HAR-13 using Bowtie2. SNPs were 
called using SAMtools/BCFtools. Phylogenies were computed with RAxML from a variable sites alignment 
using a GTR + gamma model and are midpoint rooted. The scale-bar indicates pairwise distance. Ct sequences 
are coloured by origin of the sample (“Origin”) and ompA serovar (“Serovar”). 
Figure 2. 
Single nucleotide polymorphisms on the Chlamydia trachomatis (Ct) genome specific to Amhara, Ethiopia. a) 
Single nucleotide polymorphisms (SNPs) conserved in Amhara, Ethiopia (allele frequency ≥ 0.8) and rare in 
other Ct sequences (allele frequency ≤ 0.2) were identified by comparing these Ct sequences (n = 99) to ocular 
genomes from other populations (n = 213). b) Logistic regression found SNPs specific to this Amharan 
population to be dispersed throughout the genome (n = 116). c) Five genes harboured three Amhara-specific 
SNPs, putative function was determined by reference to published literature. 
Figure 3. 
Polymorphisms on the Chlamydia trachomatis (Ct) genome associated with village-level TF prevalence. a) No 
single nucleotide polymorphisms were significantly associated with village-level TF prevalence. b) Eight 
polymorphic regions from positions 774,000 to 791,000 were associated with village-level prevalence of TF. 
Figure 4. 
Geographical distribution and similarity of ompA serovars. a) Four zones in Amhara, Ethiopia were represented 
in this study. Pie charts represent village-level Ct prevalence (pie diameter) and presence of ompA serovars A 
(red) and B (blue). Maps were generated using R package ggmap, shape files were obtained from Google Maps.  
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Table 1. Demographic and trachoma characteristics of complete and sequenced samples, Amhara, 
Ethiopia, 2011-2015 
 Complete dataset 
(n = 240) 
Sequenced dataset 
(n = 99) 
Median age, range (years) 3 (1-5) 3 (1-5) 
Female; n (%) 224 (52·6) 48 (48·5) 
Zone; n (%) 
East Gojam 
North Gondar 
South Gondar 
Waghemra 
 
100 (41·7) 
22 (9·2) 
69 (28·8) 
49 (20·4) 
 
43 (43·4) 
12 (12·1) 
26 (26·3) 
18 (18·2) 
Median cluster TF1 prevalence, range (%) 58·8 (13·5-90·7) 58·7 (15·3-90·7) 
Median cluster TI2 prevalence, range (%) 14·9 (0·0-51·4) 15·4 (0·0-51·4) 
Median cluster Ct prevalence, range (%) 28·0 (4·0-100·0) 24·0 (4·0-100·0) 
Median load of infection, range3 368.9 (27·29-2·49x106) 1431.2 (213·67-1·26x106) 
1
trachomatous inflammation-follicular, 
2
trachomatous inflammation-intense, 
3
elementary bodies per swab 
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Table 2. Description of nucleotide polymorphisms and amino acid changes in ompA of Amharan Ct 
sequences. 
ompA Type 
(number) 
Nucleotide Position and Reference Nucleotide 
(Amino Acid Position and Reference Amino Acid) 
 Serovar A Serovar B 
 272G 
(91S) 
305C 
(102A) 
433A 
(145T) 
736A 
(246I) 
940A 
(314K) 
943C 
(315P) 
946G 
(316V) 
955A 
(319T) 
956C 
(319T) 
286A 
(96T) 
1132G 
(378A) 
A1 (5) A 
(Asp) 
  G (Ile)        
A2 (2)   G (Ala) G (Ile)        
A3 (21)    G (Ile)        
A4 (1)     G (Glu) G (Ala) A 
(Ile) 
G (Val) T (Val)   
A5ref (22)            
A6 (1)  T 
(Val) 
         
B1 (6)          G 
(Ala) 
A 
(Thr) 
B2 (6)           A 
(Thr) 
B3ref (35)            
ref
reference type per serovar to determine classify variants 
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Table 3. Linear regression analysis of predictors of district-level ompA diversity. 
 Univariate Multivariate 
Variable1 β2 SE3 p-value β SE p-value 
Ct infection prevalence 1·134 0·238 0·69x10-4 0·402 0·114 0·002 
TF prevalence 0·005 0·004 0·159 -0·004 0·004 0·275 
TI prevalence 0·033 0·012 0·008 0·016 0·013 0·260 
1
district-levels prevalence estimates, 
2
β = regression coefficient, 
3
SE = standard error 
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Figure 1 
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Figure 2 
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Figure 3 
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